News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers:
Bath & Beyond (NASDAQ: BBBY) 99.9% HIGHER; Ryan Cohen, a co-founder of Chewy (NYSE: CHWY) and Chairman of GameStop (NYSE: GME), has a 9.8% stake in Bed Bath & Beyond (NASDAQ: BBBY), filings showed.
TherapeuticsMD, Inc. (NASDAQ: TXMD) 57% HIGHER; Entered into a definitive agreement to divest its vitaCare Prescription Services (vitaCare) business to GoodRx (Nasdaq: GDRX), a consumer-focused digital healthcare platform. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) 19.7% LOWER; announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies.
Squarespace, Inc. (NYSE: SQSP) 19% LOWER; reported Q4 net loss of $16.3 million. Revenue for the quarter came in at $207.4 million versus the consensus estimate of $205.39 million. Squarespace, Inc. sees FY2022 revenue of $862-878 million.
bluebird bio (NASDAQ: BLUE) 13.6% LOWER; On March 4, 2022, Gina Consylman, Chief Financial Officer and Treasurer and the principal financial officer of bluebird bio, Inc., provided notice of her resignation from bluebird, effective April 3, 2022. The Company expects to appoint Jason F. Cole, the Company’s Chief Business Officer, to serve as principal financial officer.
Gilead Sciences, Inc. (Nasdaq: GILD) 5.2% LOWER; today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint with a statistically significant improvement in progression-free…